Stock Quote
Acorda Therapeutics, Inc. (ACOR.O) (Consolidated Issue listed on NASDAQ Global Market)
$24.37
25 Nov 2009
+0.29%
$24.37
--
325,020
$24.58
$24.29
$29.27
$14.89
0.84
414,420
ACOR.O
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Cohen, Ron | President,Chief Executive Officer, Director | 1,577,880 |
| Lawrence, David | Chief Financial Officer | 961,860 |
| Wasman, Jane | Executive Vice President, General Counsel, Secretary | 1,046,810 |
Profile
Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the central... Full Description
Company Address
Acorda Therapeutics, Inc.
15 Skyline Drive
Hawthorne NY 10532
P: +1914.3474300
F: +1914.3474560
15 Skyline Drive
Hawthorne NY 10532
P: +1914.3474300
F: +1914.3474560
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Biogen Idec Inc. | $47.45 | +0.07 |
| Schering-Plough Corporation | -- | -- |
| Teva Pharmaceutical Industries Limited | ₪20,000.00 | -200.00 |
| ACOR.O | Industry | |
|---|---|---|
| P/E(TTM) | -- | 13.09 |
| P/S(TTM) | 18.57 | 31.15 |
| ROI(TTM) | -37.55 | 2.44 |
| ROE(TTM) | -57.09 | 3.70 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | -0.60 |
| EPS Est. (Current Year) | -2.22 |
| Total Revenue | $12.55M |
| Net Income | $-23.33M |
| EPS | $-0.62 |
